Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an…
Pacvue Launches Pacvue Prism, Powering the Industry’s First Agentic Commerce Grid
Shangri-La Group Debuts ‘Dragonbeat’ with Resounding Success, Cross-Industry Collaborations with Local Creators in Art, Fashion, Gastronomy and Music
EE Power Asia 2026 to Spotlight Technologies Driving the Next Era of Electrification